1. Product Introduction
Rapid CEA Test is an immunochromatographic assay for the qualitative determination of Carcinoembryonic Antigen (CEA) in human serum, plasma or whole blood.
CEA tests can have significant value in the monitoring of patients. Progressive elevations of CEA may herald tumor recurrence 3-36 months before clinical evidence of metastases. Persistent elevation in circulating CEA following treatment is strongly indicative of occult metastatic and/or residual disease. A persistent rising CEA value may be associated with progressive malignant disease and poor therapeutic response. A declining CEA value is generally indicative of a favorable prognosis and good response to treatment. Measurement of CEA has been shown to be clinically relevant in the follow-up management of patients with colorectal, breast, lung, prostatic, pancreatic, ovarian, and other carcinomas. Follow-up studies of patients with colorectal, breast and lung carcinomas suggest that the preoperative CEA level has prognostic significance. CEA testing is not recommended as a screening procedure to detect cancer in the general population; however, use of the CEA test as an adjunctive test in the prognosis and management of cancer patients is widely accepted.